Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.

•Baseline symptom scores were low and similar in the two treatment arms.•Symptoms improved from baseline until treatment discontinuation in both arms.•Chest pain improved significantly more with osimertinib than with erlotinib/gefitinib.•No symptom improvements reached the predefined clinical relevance threshold.